IMMX
Immix Biopharma Inc
NASDAQ: IMMX · HEALTHCARE · BIOTECHNOLOGY
$8.93
+3.48% today
Updated 2026-04-30
Market cap
$505.20M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.89
Dividend yield
—
52W range
$2 – $12
Volume
0.7M
Immix Biopharma Inc (IMMX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $-89.52M | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | +100.0% | — | — |
| Cost of revenue | $1082.00 | $2321.00 | $2468.00 | $2135.00 | $5468.00 | $115388.00 | $364501.00 |
| Gross profit | $-1082.00 | $-2321.00 | $-2468.00 | $-89.52M | $-5468.00 | $-115388.00 | $-364501.00 |
| Gross margin | — | — | — | 100.0% | — | — | — |
| R&D | $583162.00 | $248149.00 | $126527.00 | $4.20M | $8.74M | $11.29M | $16.26M |
| SG&A | $259337.00 | $205703.00 | $1.23M | $4.02M | $7.41M | $11.38M | $13.70M |
| Operating income | $-842499.00 | $-453852.00 | $-1.35M | $-8.22M | $-16.14M | $-22.67M | $-27.21M |
| Operating margin | — | — | — | 9.2% | — | — | — |
| EBITDA | $-841417.00 | $-451531.00 | $-24.20M | $-8.22M | $-16.14M | $-22.56M | $-26.85M |
| EBITDA margin | — | — | — | 9.2% | — | — | — |
| EBIT | $-842499.00 | $-453852.00 | $-24.20M | $-8.22M | $-16.14M | $-22.67M | $-27.21M |
| Interest expense | $109984.00 | $101976.00 | $179853.00 | $497.00 | $0.00 | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-972811.00 | $-1.15M | $-24.38M | $-8.23M | $-15.43M | $-21.61M | $-29.44M |
| Net income growth (YoY) | — | -18.0% | -2024.3% | +66.2% | -87.4% | -40.1% | -36.2% |
| Profit margin | — | — | — | 9.2% | — | — | — |